Citation Impact
Citing Papers
Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection
2018 Standout
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results
2013
Identification of a Small Interface between the Methyltransferase and RNA Polymerase of NS5 that is Essential for Zika Virus Replication
2018 StandoutNobel
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Electrocardiogram generation with a bidirectional LSTM-CNN generative adversarial network
2019 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2019
2019 Standout
Cancer Statistics, 2021
2021 Standout
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
2012 Standout
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
2020
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
2013
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Influenza-Associated Hospitalizations in the United States
2004 Standout
Direct-acting and host-targeting HCV inhibitors: current and future directions
2012
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
2011
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia
2006 Standout
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
2013 StandoutNobel
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
2012
Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations
2003
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young Children
2007 Standout
Strategies for containing an emerging influenza pandemic in Southeast Asia
2005 StandoutNature
Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT).
1996
Burden of Interpandemic Influenza in Children Younger than 5 Years: A 25‐Year Prospective Study
2002
In Vivo Emergence of a Novel Mutant L159F/L320F in the NS5B Polymerase Confers Low-Level Resistance to the HCV Polymerase Inhibitors Mericitabine and Sofosbuvir
2013
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
2013
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
2012
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
2011
Severe Sepsis and Septic Shock
2013 Standout
The role of resistance in HCV treatment
2012
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
2012
Antiviral chemotherapeutic agents against respiratory viruses
2004
Seasonal influenza: The burden of disease in children
2011
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
2011
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
2012
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Sensorineural hearing loss in children
2005 Standout
Treating viral hepatitis C: efficacy, side effects, and complications
2006
Antiviral strategies in hepatitis C virus infection
2012
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
2005 Standout
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Treatment of hepatitis C in difficult-to-treat patients
2015
Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies
2008
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
2011
Hepatitis C Virus-Specific Directly Acting Antiviral Drugs
2013
Does Medicare Save Lives?*
2009 StandoutNobel
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders
2007
FluSTAR, A Novel Influenza Surveillance System: Outcomes from the 2005–2006 Flu Season
2007
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
2005
The dawn of a new era in HCV therapy
2011
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
2003 Standout
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
2013
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
Obstructive sleep apnoea and its cardiovascular consequences
2008 Standout
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C
2013
Influenza Viruses Resistant to the Antiviral Drug Oseltamivir: Transmission Studies in Ferrets
2004
Treatment of HCV Infection by Targeting MicroRNA
2013 Standout
Treatment of Chronic Hepatitis C: Current and Future
2013
Current race in the development of DAAs (direct-acting antivirals) against HCV
2014
The use of antiviral agents for the management of severe influenza
2010
Rapid Diagnostic Assay for Intact Influenza Virus Using a High Affinity Hemagglutinin Binding Protein
2017 StandoutNobel
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
2020 Standout
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
2006 Standout
Ultrastructural analysis of hepatitis C virus particles
2013 StandoutNobel
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Otitis media
2004
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans
2009 Standout
Insights into the Interaction between Influenza Virus and Pneumococcus
2006
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
MOLECULAR MECHANISMS OF PROSTAGLANDIN TRANSPORT
1998
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
2001 StandoutScience
Hepatitis C Virus Evasion Mechanisms from Neutralizing Antibodies
2011
Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department: Results of a Randomized, Prospective, Controlled Trial
2003
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development
2014
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells
2019 StandoutNobel
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect
2014
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
New therapeutic strategies in HCV: second‐generation protease inhibitors
2013
Novel Therapies for Hepatitis C: Insights from the Structure of the Virus
2011
Airborne transmission of respiratory viruses
2021 StandoutScience
Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission
2013 StandoutNobel
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus
2016 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2001 Standout
Works of David Ipe being referenced
Computerized Extraction of Electrocardiograms From Continuous 12‐Lead Holter Recordings Reduces Measurement Variability in a Thorough QT Study
2011
Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C
2012
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
2010
Oral oseltamivir treatment of influenza in children
2001
Propel: A Randomized Trial of Mericitabine Plus Peginterferon Alpha-2a/Ribavirin Therapy in Treatment-NaïVe HCV Genotype 1/4 Patients
2013
Gastric Ulcer Healing
1991
1323 THE EFFECT OF HOST IL28B GENOTYPE ON EARLY VIRAL KINETICS DURING INTERFERON-FREE TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC)
2011
1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY
2012
Oral Oseltamivir in Human Experimental Influenza B Infection
2000
731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patients
2006
1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL
2011